|
Tuesday, 29 May 2007 |
|
A Canadian woman has filed a class action Fosamax lawsuit against the manufacturer of the osteoporosis drug. The woman alleges that Merck Frosst Canada, the Canadian branch of Merck & Co., failed to adequately warn patients that Fosamax could cause a condition known as osteonecrosis of the jaw (ONJ). |
|
Read more...
|
|
|
Thursday, 03 May 2007 |
|
Two new studies have suggested a link between the osteoporosis drug Fosamax and an increased risk of irregular heart rhythms. The studies were published today in the New England Journal of Medicine. |
|
Read more...
|
|
|
Tuesday, 06 February 2007 |
|
Merck & Co., the manufacturer of Fosamax, says that it preparing for a flood of Fosamax lawsuits it expects will soon be filed by former patients. The company has announced that it has sent aside $48 million to defend itself against charges that Fosamax caused patients to develop a painful condition known as osteonecrosis of the jaw, or jaw necrosis. |
|
Read more...
|
|
|
Tuesday, 09 January 2007 |
|
A leading research journal has revealed that a recent study about the health benefits of the osteoporosis drug Fosamax was funded by manufacturer Merck & Co., raising questions about the accuracy of its findings. The study, “Effects of Continuing or Stopping Alendronate After 5 Years of Treatment,” claimed that Fosamax would continue to prevent bone loss for five years in patients who stopped taking Fosamax after five years of treatment. |
|
Read more...
|
|
|
Monday, 18 December 2006 |
|
Some dentists say that they are seeing an increase in patients with a painful jaw condition which may be associated with the osteoporosis drug Fosamax. The condition, known as osteonecrosis of the jaw, or jaw necrosis, causes the death of jawbone tissue. Patients with this extremely painful condition may eventually need to have their jawbone removed in order to this potential side effect of Fosamax. |
|
Read more...
|
|
|
|
<< Start < Prev 1 2 Next > End >>
|
| Results 10 - 18 of 18 |